Process analytical technologies’ (PAT) economic benefit

Dr. Peter G. Martin, author and authority on real-time performance management and vice president of performance management at Invensys Process Systems, presented a seminar entitled "Optimizing PAT with Metrics that Matter," on Nov. 9, 2005, to members of the International Society for Pharmaceutical Engineers (ISPE) at its annual meeting.

By Staff January 1, 2006

Dr. Peter G. Martin, author and authority on real-time performance management and vice president of performance management at Invensys Process Systems, presented a seminar entitled “Optimizing PAT with Metrics that Matter,” on Nov. 9, 2005, to members of the International Society for Pharmaceutical Engineers (ISPE) at its annual meeting.

“With PAT, the U.S. Food and Drug Administration has opened the door for pharmaceutical manufacturers to achieve the performance optimization benefits that are already being realized in many other industries,” said Janice Abel, director of pharmaceutical and biopharmaceutical marketing for Invensys and past president of the ISPE Boston chapter.

The seminar intended to guide pharmaceutical and biopharmaceutical professionals on how to implement programs to realize measurable benefits from PAT-related process optimization. Martin demonstrated ways of developing measures that correlate with meaningful business metrics to help life-science developers and manufacturers cut costs, improve product quality, or speed to market, depending on their business strategy.